T2 Biosystems, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 32 rows in 2016. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2016-09-21: Reporting owner LIEBMAN SEYMOUR; Form 4; Security Stock Option (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2016-09-06: Reporting owner Spadoro Joanne; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2016-06-30: Reporting owner Dhanda Rahul; Form 4; Security Stock Option (Right to Buy); Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2016-06-17: Reporting owner Lapidus Stanley; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2016-09-21 | LIEBMAN SEYMOUR Director | 4 | Stock Option (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +66,176 66,176 owned after | $6.50 exercise price | 2016-09-22 | |
| 2016-09-06 | Spadoro Joanne Officer (Chief Operations Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +146,600 146,600 owned after | $6.84 exercise price | 2016-09-08 | |
| 2016-06-30 | Dhanda Rahul Officer (SVP of Corporate Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −3,589 31,705 owned after | $2.45 exercise price | 2016-07-05 | |
| 2016-06-17 | Lapidus Stanley Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,647 17,647 owned after | $8.56 exercise price | 2016-06-27 | |
| 2016-06-17 | Cima Michael J. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,647 17,647 owned after | $8.56 exercise price | 2016-06-21 | |
| 2016-06-17 | Bilenker Joshua H. Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,647 17,647 owned after | $8.56 exercise price | 2016-06-21 | |
| 2016-06-17 | CUMMING JOHN W Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,647 17,647 owned after | $8.56 exercise price | 2016-06-21 | |
| 2016-06-17 | WILCOX HARRY W Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,647 17,647 owned after | $8.56 exercise price | 2016-06-21 | |
| 2016-06-17 | Elsbree David B Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +17,647 17,647 owned after | $8.56 exercise price | 2016-06-21 | |
| 2016-05-16 | Lynch Shawn Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +146,600 146,600 owned after | $8.88 exercise price | 2016-05-17 | |
| 2016-05-01 | DEPTULA-HICKS DARLENE M Officer (Chief Financial Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +175,000 175,000 owned after | $4.74 exercise price | 2017-05-02 | |
| 2016-03-16 | Dhanda Rahul Officer (SVP of Corporate Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −4,647 0 owned after | $1.16 exercise price | 2016-03-18 | |
| 2016-03-16 | Dhanda Rahul Officer (SVP of Corporate Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,941 0 owned after | $1.31 exercise price | 2016-03-18 | |
| 2016-03-15 | Dhanda Rahul Officer (SVP of Corporate Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −13,770 0 owned after | $1.96 exercise price | 2016-03-17 | |
| 2016-03-14 | Dhanda Rahul Officer (SVP of Corporate Development) | 4 | Stock Option (Right to Buy) Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | +2,700 13,770 owned after | $1.96 exercise price | 2016-03-16 | |
| 2016-03-09 | GOLDMAN SACHS GROUP INC | GOLDMAN SACHS & CO 10% Owner | 10% Owner | 4 | Non Qualified Stock Option (Right to Buy) Derivative · Indirect · See footnotes | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +66,176 66,176 owned after | $8.92 exercise price | 2016-03-11 | |
| 2016-03-09 | Jones Adrian M Director | 4 | Non-Qualified Stock Option (Right to Buy) Derivative · Indirect · See footnotes | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +66,176 66,176 owned after | $8.92 exercise price | 2016-03-11 | |
| 2016-02-22 holding as of filing | Dhanda Rahul Officer (SVP of Corporate Development) | 3 | Stock Option Derivative · Direct | Holding | $0.48 exercise price | 2016-02-22 | ||
| 2016-02-22 holding as of filing | Dhanda Rahul Officer (SVP of Corporate Development) | 3 | Stock Option Derivative · Direct | Holding | $1.16 exercise price | 2016-02-22 | ||
| 2016-02-22 holding as of filing | Dhanda Rahul Officer (SVP of Corporate Development) | 3 | Stock Option Derivative · Direct | Holding | $1.31 exercise price | 2016-02-22 | ||
| 2016-02-22 holding as of filing | Dhanda Rahul Officer (SVP of Corporate Development) | 3 | Stock Option Derivative · Direct | Holding | $1.96 exercise price | 2016-02-22 | ||
| 2016-02-22 holding as of filing | Dhanda Rahul Officer (SVP of Corporate Development) | 3 | Stock Option Derivative · Direct | Holding | $2.45 exercise price | 2016-02-22 | ||
| 2016-02-22 holding as of filing | Dhanda Rahul Officer (SVP of Corporate Development) | 3 | Stock Option Derivative · Direct | Holding | $3.22 exercise price | 2016-02-22 | ||
| 2016-02-22 holding as of filing | Dhanda Rahul Officer (SVP of Corporate Development) | 3 | Stock Option Derivative · Direct | Holding | $10.70 exercise price | 2016-02-22 | ||
| 2016-02-22 holding as of filing | Dhanda Rahul Officer (SVP of Corporate Development) | 3 | Stock Option Derivative · Direct | Holding | $19.95 exercise price | 2016-02-22 | ||
| 2016-02-22 holding as of filing | Dhanda Rahul Officer (SVP of Corporate Development) | 3 | Stock Option Derivative · Direct | Holding | $7.56 exercise price | 2016-02-22 | ||
| 2016-01-26 holding as of filing | Gibbs Michael Terrence Officer (General Counsel) | 3 | Stock Option Derivative · Direct | Holding | $17.01 exercise price | 2016-01-26 | ||
| 2016-01-20 | Pfaller Michael A. Officer (Chief Medical Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +20,000 20,000 owned after | $9.02 exercise price | 2016-01-26 | |
| 2016-01-20 | Kalil Sarah O. Officer (Chief Operating Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +40,000 40,000 owned after | $9.02 exercise price | 2016-01-26 | |
| 2016-01-20 | Gibbs Michael Terrence Officer (General Counsel) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +60,000 60,000 owned after | $9.02 exercise price | 2016-01-26 | |
| 2016-01-20 | McDonough John Director, Officer (President & CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +133,334 133,334 owned after | $9.02 exercise price | 2016-01-26 | |
| 2016-01-20 | Lowery Thomas J. Officer (Chief Scientific Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +58,800 58,800 owned after | $9.02 exercise price | 2016-01-26 |